MGNX
MGNX
NASDAQ · Biotechnology

Macrogenics Inc

$4.06
+0.32 (+8.56%)
As of Sep 28, 10:21 PM ET ·
Financial Highlights (FY 2026)
Revenue
153.21M
Net Income
-76,469,178
Gross Margin
75.9%
Profit Margin
-49.9%
Rev Growth
-0.5%
D/E Ratio
1.26
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 75.9% 75.9% 35.0% 35.0%
Operating Margin -48.7% -43.8% 23.3% 21.2%
Profit Margin -49.9% -47.4% 20.8% 16.7%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 153.21M 154.03M 19.43M 16.17M
Gross Profit 116.30M 116.92M 6.80M 5.66M
Operating Income -74,644,004 -67,537,552 4.53M 3.44M
Net Income -76,469,178 -69,188,961 4.04M 2.70M
Gross Margin 75.9% 75.9% 35.0% 35.0%
Operating Margin -48.7% -43.8% 23.3% 21.2%
Profit Margin -49.9% -47.4% 20.8% 16.7%
Rev Growth -0.5% -0.5% +14.5% +17.0%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 67.46M 67.46M 6.65M 6.76M
Total Equity 53.57M 53.57M 36.37M 40.78M
D/E Ratio 1.26 1.26 0.18 0.17
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -67,298,055 -64,273,803 6.14M 4.71M
Free Cash Flow — — 2.37M 2.40M